New Survey Finds Younger Adults, More Women Seeking Treatment for Hair Loss
Manageable number of monthly hair restoration surgeries illustrates ISHRS members ' hands-on, expert approach CHICAGO, June 10, 2025 /PRNewswire/ -- According to results of a new member survey conducted by the International Society of Hair Restoration Surgery (ISHRS), first-time hair restoration surgery patients in 2024 skewed younger than the...
Akesis Biologics Launches MastGut: A Breakthrough Supplement That Uses DUSP10 Enzyme to Support Gut and Colorectal Health
SINGAPORE, June 10, 2025 /PRNewswire/ -- Akesis Biologics, a biotechnology spin-off from the National University of Singapore (NUS), has officially launched its flagship gut health product, MastGut — a pioneering supplement that delivers therapeutic protection directly to the gut. Built on years of academic research and published findings in Nature Oncogene, MastGut brings an innovative approach to the...
Echosens and Boehringer Ingelheim Expand Long-Standing Collaboration to Accelerate Progress in MASH Diagnosis and Care
PARIS, June 10, 2025 /PRNewswire/ -- As metabolic dysfunction-associated steatohepatitis (MASH) emerges as one of the most dangerous and underdiagnosed drivers of liver failure—affecting more than 250 million people worldwide—Echosens, the leader in non-invasive liver diagnostics, and Boehringer Ingelheim, a global biopharmaceutical company, today announced an expansion of their long-standing partnership...
Eluminex Biosciences Announces Phase 1b Single Ascending Dose Study Results of a Novel Pentavalent Trispecific Fusion Antibody (EB-105) in Patients with Diabetic Macular Edema (DME)
EB-105 Targets VEGF-A, -B, PlGF, Ang-2, and IL-6R Improvements in Visual Acuity and Retinal Edema Observed at All Dose Levels No Safety Issues Observed Following a Single Intravitreal (IVT) Injection Multiple Ascending Dose Study Planned for Q3 2025 in DME MOUNTAIN VIEW, Calif., June 10, 2025 /PRNewswire/ -- Eluminex Biosciences Limited, a clinical-stage protein therapeutics company announced...
VivaVision Announces Positive Comments from FDA for the Type C Meeting Regarding VVN461LD for Post-operative Infalmmation – Agreeing the Phase 2 Trial to Be Served as One of the...
HONG KONG and WENZHOU, China, June 10, 2025 /PRNewswire/ -- VivaVision Biotech (VivaVision), a late clinical-stage, privately-held biotech company focused on developing innovative ophthalmic drugs, announced today that it received written preliminary comments for the Type C meeting to be held in early June, 2025 with the United States Food and Drug Administration (FDA). A Type C meeting is a...
World’s First HLA-G Targeted Exosome Therapy for Cancer Enters U.S. Clinical Trials
FDA Greenlights SOB100 for Phase I; Breakthrough Study Published in Nature Communications TAICHUNG, June 9, 2025 /PRNewswire/ -- A research team led by Dr. Der-Yang Cho, Superintendent of China Medical University Hospital (Taiwan), in collaboration with Shine-On Biomedical Co., has developed the world's first targeted exosome drug delivery platform aimed at HLA-G, marking a major milestone in the field of...
Planet Green Advances AI-Powered Early Mental Health Intervention for Youth in Post-Pandemic Canada
NEW YORK, June 9, 2025 /PRNewswire/ -- Planet Green Holdings Corp. ("Planet Green", the "Company") (NYSE American: PLAG) announced that its subsidiary Fast Approach Inc., ("Fast Approach"), a leader in applied AI technology, today announced a groundbreaking initiative in mental healthcare: the development of AI-driven conversational agents designed to support early-stage intervention for anxiety and depression, particularly among adolescents. The...
Neowise Biotechnology and BeOne Medicines Enter Licensing Agreement to Advance Development of Next-Generation Cell Therapies
SUZHOU, China, June 9, 2025 /PRNewswire/ -- Neowise Biotechnology ("Neowise"), a pioneering company focused on the development of TCR-T cell therapies for solid tumors, announced today that it has entered into a non-exclusive licensing agreement with BeOne Medicines Ltd. ("BeOne"). Under the terms of the agreement, Neowise will grant BeOne rights to one of its proprietary antigen-specific TCR molecules...
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
TAIPEI, June 9, 2025 /PRNewswire/ -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW), today announced a licensing agreement, whereby Harrow has acquired the exclusive U.S. commercial rights for BYQLOVI™ (clobetasol propionate ophthalmic suspension) 0.05%. BYQLOVI was recently approved by the U.S. Food and...
Microtech Announces the First U.S. Atrial Microsensor Implantations as Part of its FIH Study
TEL AVIV, Israel, June 9, 2025 /PRNewswire/ -- Microtech, a wholly owned subsidiary of Medinol, is happy to announce the first U.S. implantations of its atrial-pressure microsensor. Two surgical implantations were performed on Friday, May 16, 2025, at New York-Presbyterian/Columbia University Irving Medical Center by Dr. Koji Takeda, Surgical Director for Adult Heart Transplant at New York-Presbyterian/Columbia. The...
